A scientific study was done to illustrate the effect of Mr. Mahendra Kumar Trivedi’s unique biofield energy treatment also known as The Trivedi Effect® on Streptococcus agalactiae group B (S. agalactiae gr. B) with respect of antimicrobial sensitivity, biochemical reactions and biotyping. The findings of this study has already been published in a reputed peer-reviewed International journal entitled “Microbial & Biochemical Technology”. Based on statistics in U.S. 2014 shows that the rate of early onset group B Strep infections (babies aged 0-6 days) remains at 0.24 cases per 1,000 live births. The rate of late-onset group B Strep infections (babies aged 7-90 days) was 0.27 cases per 1,000 live births in the U.S. It is found as part of the normal gut flora in 20-30% of people (men and women), and ‘colonises’ the vagina in roughly 22% of all women. Although GBS can be passed through sexual contact, it is not a sexually transmitted disease. In this study, the minimum inhibitory concentration of S. agalactiae gr. B showed significant (70.37%) alteration, of tested antimicrobials as compared to the control. Moreover, the improvement of MIC value of norfloxacin was observed by two-fold (8 to ≤4 µg/mL) in biofield energy treated group as compared to the control. It was also observed that overall 48.28% biochemical reactions, were altered in the biofield treated group with respect to the control. Moreover, biotype numbers were also changed in the treated group as compared to the control. In conclusion, Mr. Trivedi’s biofield energy treatment has significant effects on Streptococcus Gr. B with respect to antibiotic susceptibility. Moreover, it would be more beneficial in pregnant woman and simultaneously able to safeguard children from detrimental effect of this infections as compared to the existing therapeutics.
Here is the link to this groundbreaking experiment. Trivedi Science has one again painted the skies with new opportunities and given the healthcare system a new weapon to fight against diseases.